direct ELISA: 1:10,000 using using 20 μg/ml of purified digoxin-BSA for coating and pNPP substrate direct ELISA: 1:6,000 using using 10 μg/ml of digoxigenin-transferrin for coating and pNPP substrate dot blot: 1:20,000 using digoxigenin-labeled biomolecules (chemiluminescent)
Cervical cancer is a major problem in women and it is important to find a suitable and acceptable screening method, especially among young in low-resource areas for future human papillomavirus (HPV) vaccine follow-up investigations. The study sought to test the
The New England journal of medicine, 336(8), 525-533 (1997-02-20)
The role of cardiac glycosides in treating patients with chronic heart failure and normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and hospitalization in a randomized, double-blind clinical trial. In the main trial, patients with
High-risk human papillomavirus (hr-HPV) infections and low-grade squamous intraepithelial lesions occur frequently in young women. The available vaccines cover up to seven hr-HPV genotypes (HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58) and two low-risk HPV types (HPV6 and HPV11).
Background: Asparaginase (ASP) is the cornerstone drug in the treatment of extranodal NK/T-cell lymphoma (ENKTCL), and the mechanisms of resistance to ASP remain largely unknown. Long non-coding RNAs play important roles in chemotherapy resistance in various cancers. However, the expression
Self-sampling for human papillomavirus testing among rural young women of KwaZulu-Natal, South Africa